Physicians' Academy for Cardiovascular Education

Diabetes & CVD

Diabetes type II confers an increased CVD risk. Recent scientific developments have yielded antidiabetic agents that positively impact CV risk in diabetic patients. Follow the latest insights into the close link between diabetes and CVD.

Identifying and treating iron deficiency in heart failure

10' education - Nov. 17, 2022 - Robert J. Mentz, MD & Prof. Peter van der Meer, MD, PhD

Looking beyond diabetes: The role of SGLT2i and MRAs in cardiorenal disease

10' education - Nov. 17, 2022 - Prof. Mikhail Kosiborod, MD

Reducing morbidity and mortality in patients with CKD and T2DM

10' education - Nov. 14, 2022 - Pam Taub, MD, Prof. George Bakris, MD, and Prof. Gerasimos Filippatos, MD

A new option for cardiorenal protection for patients with CKD and T2DM

10' education - Nov. 14, 2022 - Prof. Gerasimos S. Filippatos, MD, Javier Morales, MD, and Angela Yee-Moon Wang, MD, PhD

Identification and management of patients with HFpEF and diabetes

10' education - Oct. 26, 2022 - Prof. Silvio Inzucchi, MD & Prof. Pardeep Jhund, MD, PhD

HFpEF and diabetes: What are the clinical challenges?

10' education - Oct. 25, 2022 - Prof. Pardeep Jhund, MD, PhD

SGLT2i in HFmrEF and HFpEF across the spectrum of glycemia

10' education - Oct. 24, 2022 - Prof. Silvio Inzucchi, MD

The spectrum of therapeutic options: which therapies to consider?

10' education - Oct. 18, 2022 - Prof. Ulf Landmesser, MD

2022 ADA/EASD consensus report on management of hyperglycemia in T2DM

3' education - Sep. 29, 2022 - Prof. John Buse, MD, PhD

SGLT2i reduces outcomes in HFmrEF and HFpEF regardless of glycemic status

3' education - Sep. 22, 2022 - Prof. Pardeep Jhund, MD, PhD

Consistent beneficial effect with GLP-1RA across broad range of kidney function and kidney damage

3' education - Sep. 21, 2022 - Prof. Peter Rossing, MD

Triglycerides most commonly a marker of ectopic fat accumulation

5' education - July 20, 2022 - Prof. Naveed Sattar, MD, PhD

Primary care as gatekeeper in CKD and the need for collaboration with nephrologists

10' education - July 13, 2022 - Prof. Kamlesh Khunti, MD, PhD

Discussion - Preventing CKD in patients with diabetes - Exploring the current and future role of GLP-1RA

10' education - July 6, 2022 - Prof. Johannes Mann, MD, prof. Filip Knop, MD, PhD, and prof. Katherine Tuttle, MD

Why is early screening and risk identification of CKD in diabetes important?

10' education - July 6, 2022 - Rikke Borg, MD, PhD

Clinical dialogue: Lowering ASCVD risk in a patient with T2DM and obesity

15' education - July 5, 2022 - Prof. Nikolaus Marx, MD and Adie Viljoen, MD

Barriers for preventing CKD in patients with diabetes

10' education - June 28, 2022 - Prof. Christoph Wanner, MD

Clinical dialogue: CV risk in diabetes

15' education - June 22, 2022 - Prof. Nikolaus Marx, MD and Michael Lehrke, MD

Which patients with CKD and diabetes will benefit from management with GLP-1RA?

10' education - June 13, 2022 - Prof. Katherine Tuttle, MD

What is relevant for nephrology with regard to GLP-1RA in CVD?

10' education - June 10, 2022 - Prof. Filip Knop, MD, PhD

Cardiorenal effects of nonsteroidal MRAs in patients with CKD and T2DM

10' education - June 7, 2022 - Eugene E. Wright, Jr., MD, Jolanta Małyszko, MD, PhD and María José Soler, MD, PhD

GLP-1RA as new treatment option on the horizon for obesity

3' education - May 31, 2022 - Prof. Ulrich Laufs, MD, PhD

New insights and guidelines for the management of CKD and diabetes

10' education - May 31, 2022 - Prof. Johannes Mann, MD

Wide distribution of CVD-free life-years gained with GLP-1RA

5' education - Mar. 21, 2022 - Jan Westerink, MD, PhD

Role of a non-steroidal MRA in the treatment spectrum of patients with T2DM and CKD

10' education - Feb. 8, 2022 - Prof. Peter Rossing, MD, prof. Gerasimos Filippatos, MD and prof. Matthew Weir, MD

Rethinking responsibilities in the prevention and management of cardiometabolic disease

10' education - Dec. 7, 2021 - Prof. Stephan Jacob, MD

What is the effect of low-dose aspirin on dementia risk in T2DM?

3' education - Nov. 16, 2021 - Prof. Jane Armitage

Symposium on the role of SGLT2i in tackling cardiorenal risk in diabetes

15' education - Oct. 28, 2021 - Prof. Melanie Davies, MD and prof. Nikolaus Marx, MD - Online CME

Dialogue on how to overcome clinical inertia with regard to SGLT2i

10' education - Oct. 28, 2021 - Prof. Melanie Davies, MD and prof. Nikolaus Marx, MD - Online CME

SGLT2i: Overview of recent trials and guideline recommendations

10' education - Oct. 28, 2021 - Prof. Nikolaus Marx, MD - Online CME

FDA approves label update of GLP-1RA as first-line option for T2DM

News - Jan. 16, 2023

A label update for the GLP-1RA semaglutide has been approved by the FDA, which allows use of semaglutide as a first-line option for adults with T2DM.

Association between cumulative systolic blood pressure load and MACE in T2DM

Literature - Jan. 5, 2023 - Wang N et al. - J Am Coll Cardiol. 2022

In a post-hoc analysis of the ADVANCE trial, cumulative SBP load was a better predictor of the occurrence of MACE in patients with T2DM compared with other BP measures.

ASCVD history does not modify nonsteroidal MRA’s cardiorenal effects in T2DM and CKD

Literature - Nov. 29, 2022 - Filippatos G, et al. - Eur Heart J Cardiovasc Pharmacother. 2022

Irrespective of a history of ASCVD, finerenone reduced the risk of CV events and CKD progression compared with placebo in patients with T2DM and CKD, as shown in a FIDELITY subgroup analysis.

Beneficial effects of non-steroidal MRA on HF-related outcomes in CKD and T2DM

Literature - Nov. 22, 2022 - Filippatos G, et al. - JACC Heart Fail. 2022

Finerenone, a non-steroidal MRA, has been approved for the treatment of CKD in adults with T2DM. Previously, the FIDELITY study showed that finerenone improves cardiorenal outcomes in these patients. But does this also apply to HF-related outcomes?

Identifying and treating iron deficiency in heart failure

10' education - Nov. 17, 2022 - Robert J. Mentz, MD & Prof. Peter van der Meer, MD, PhD
Robert Mentz and Peter van der Meer discuss approaches to identifying and treating iron deficiency in patients with heart failure and comorbidities such as diabetes.

Robert Mentz and Peter van der Meer discuss approaches to identifying and treating iron deficiency in patients with heart failure and comorbidities such as diabetes.

Looking beyond diabetes: The role of SGLT2i and MRAs in cardiorenal disease

10' education - Nov. 17, 2022 - Prof. Mikhail Kosiborod, MD
Prof. Kosiborod reviews the current challenges in initiating and maintaining patients on optimal RAASi therapy and approaches to improve cardiorenal outcomes in patients with heart failure and concomitant kidney dysfunction and/or diabetes.

Prof. Kosiborod reviews the current challenges in initiating and maintaining patients on optimal RAASi therapy and approaches to improve cardiorenal outcomes in patients with heart failure and concomitant kidney dysfunction and/or diabetes.

Reducing morbidity and mortality in patients with CKD and T2DM

10' education - Nov. 14, 2022 - Pam Taub, MD, Prof. George Bakris, MD, and Prof. Gerasimos Filippatos, MD
The FIDELITY pooled analysis findings demonstrated benefits in CV and kidney outcomes with the nonsteroidal MRA finerenone. Pam Taub, Gerasimos Filippatos, and George Bakris discuss the risk factors of CKD, the importance of measuring eGFR and UACR, and how finerenone improves outcomes.

The FIDELITY pooled analysis findings demonstrated benefits in CV and kidney outcomes with the nonsteroidal MRA finerenone. Pam Taub, Gerasimos Filippatos, and George Bakris discuss the risk factors of CKD, the importance of measuring eGFR and UACR, and how finerenone improves outcomes.

A new option for cardiorenal protection for patients with CKD and T2DM

10' education - Nov. 14, 2022 - Prof. Gerasimos S. Filippatos, MD, Javier Morales, MD, and Angela Yee-Moon Wang, MD, PhD
Diabetic nephropathy is one of the leading causes of ESRD. Three experts explore recent data on the use of nonsteroidal MRAs and discuss how to prevent deterioration of renal function and improve CV outcomes across the spectrum of renal decline.

Diabetic nephropathy is one of the leading causes of ESRD. Three experts explore recent data on the use of nonsteroidal MRAs and discuss how to prevent deterioration of renal function and improve CV outcomes across the spectrum of renal decline.

Reduced worsening of kidney disease or CV death by SGLT2i in CKD patients

News - Nov. 7, 2022

AHA 2022 In the EMPA-KIDNEY trial, use of empagliflozin reduced the outcome of worsening of kidney disease or CV death compared with placebo in CKD patients. In addition, results of a meta-analysis of 13 SGLT2i trials in high-risk patients were presented.

Pemafibrate lowers triglycerides, but not CV event rates

News - Nov. 5, 2022

AHA 2022 The PROMINENT trial showed that pemafibrate reduces TG, VLDL-c, remnant cholesterol and ApoCIII in patients with T2DM, mild-to-moderate hypertriglyceridemia and low HDL-c. However, it did not reduce CV outcomes.

Identification and management of patients with HFpEF and diabetes

10' education - Oct. 26, 2022 - Prof. Silvio Inzucchi, MD & Prof. Pardeep Jhund, MD, PhD
“Heart failure is a great masquerader, it looks like lots of other conditions because some of the symptoms overlap with a lot of symptoms of other diseases” says Prof. Jhund. Together with Prof. Inzucchi he discusses the identification and treatment of patients with HFpEF.

“Heart failure is a great masquerader, it looks like lots of other conditions because some of the symptoms overlap with a lot of symptoms of other diseases” says Prof. Jhund. Together with Prof. Inzucchi he discusses the identification and treatment of patients with HFpEF.

HFpEF and diabetes: What are the clinical challenges?

10' education - Oct. 25, 2022 - Prof. Pardeep Jhund, MD, PhD
Many patients with diabetes have unrecognized HFpEF and early identification of these patients is important. Prof. Jhund talks about the clinical challenges of  HFpEF and diabetes.

Many patients with diabetes have unrecognized HFpEF and early identification of these patients is important. Prof. Jhund talks about the clinical challenges of HFpEF and diabetes.